Abstract | OBJECTIVE: METHODS: Study patients were assessed for the need for the addition of insulin, and follow-up clinical and laboratory findings were analyzed. RESULTS: At a mean follow-up of 37 months (range, 18 to 45), 26 (74%) of 35 patients (group A) had well-controlled blood glucose levels on triple oral therapy, with a mean glycated hemoglobin (HbA1c) value of 6.9 +/- 0.3% (upper limit of normal, 6.5%). In the nine other patients (group B), triple oral therapy failed and the use of insulin was necessary after a mean duration of 30 months (range, 18 to 42); the mean HbA1c in these patients was 8.8 +/- 0.5%. Both group A and B gained similar amounts of weight during the study period (14.2 +/- 2.1 lb versus 11.6 +/- 3.8 lb, respectively; P = 0.54). A search for potential predictors of success or failure revealed that both groups had similar baseline characteristics, including age, duration of diabetes, weight, body mass index, HbA1c, and baseline stimulated C-peptide levels, and none of these factors demonstrated a significant correlation with the response to therapy. The only difference found between the two groups was a significant increase in the stimulated C-peptide levels (from 3.6 +/- 0.9 ng/mL to 5.2 +/- 1.1 ng/mL; P = 0.002) during follow-up in the group that had good glycemic control with triple oral therapy, in comparison with a nonsignificant increase (from 3.7 +/- 0.8 ng/mL to 4.2 +/- 0.4 ng/mL; P = 0.46) in the group that failed to maintain glycemic control on triple oral therapy. CONCLUSION:
|
Authors | David S H Bell, Fernando Ovalle |
Journal | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
(Endocr Pract)
2002 Jul-Aug
Vol. 8
Issue 4
Pg. 271-5
ISSN: 1530-891X [Print] United States |
PMID | 12173913
(Publication Type: Journal Article)
|
Chemical References |
- C-Peptide
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Sulfonylurea Compounds
- Thiazoles
- Thiazolidinediones
- Metformin
- 2,4-thiazolidinedione
|
Topics |
- Adolescent
- Adult
- Body Mass Index
- C-Peptide
(blood)
- Diabetes Mellitus, Type 2
(drug therapy)
- Drug Therapy, Combination
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(therapeutic use)
- Metformin
(therapeutic use)
- Middle Aged
- Sulfonylurea Compounds
(therapeutic use)
- Thiazoles
(therapeutic use)
- Thiazolidinediones
- Time Factors
- Weight Gain
|